Tafasitamab

The inMIND trial showed Monjuvi + Rituxan + Revlimid improved progression-free survival (PFS) to 22.4 months vs. 13.9 months for placebo in R/R follicular lymphoma. Key secondary endpoints also favored the experimental arm. Monjuvi aims to become a new standard-of-care option, with potential competition from other therapies.

Tafasitamab-cxix (Monjuvi) demonstrated real-world effectiveness in US patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with progression-free survival (PFS) of 11.3 months and overall survival (OS) of 24.8 months. The overall response rate (ORR) was 73.5%, including 23.2% complete response (CR) and 50.3% partial response (PR). Factors increasing progression risk included later-line therapy, advanced disease stage, higher comorbidity index, and bulky disease. Increased mortality risk factors included later-line therapy, older age, higher ECOG performance status, and bulky disease. The study highlights tafasitamab's clinical benefit, particularly when used in second-line therapy.

Real-world data on tafasitamab-cxix (Monjuvi) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) showed PFS of 11.3 months and OS of 24.8 months, with an ORR of 73.5%. Factors like later-line use, advanced disease stage, higher comorbidity scores, and bulky disease increased progression risk. Tafasitamab's effectiveness was greatest in second-line therapy, with CR rates of 23.2% and PR rates of 50.3%.

Incyte presents 20 oncology data presentations at 2024 ASH Annual Meeting, including Phase 3 inMIND study results on tafasitamab in follicular lymphoma. Hosts virtual analyst and investor event on December 12, 2024.

COTA's study reveals DLBCL patients initiating treatment immediately post-diagnosis may experience worse outcomes compared to those starting later, with shorter median times to next-line therapy and overall survival rates. Presented at the 66th ASH 2024 Annual Meeting, the research also highlights higher ECOG scores and high-risk clinical features in these patients, emphasizing the need for informed future trials and practices.

Incyte pauses Phase 2 study of INCB000262 due to toxicology findings, and scraps INCB000547 after Phase 2 results. These setbacks impact Incyte's diversification efforts from Jakafi, which faces competition and patent issues. Investors focus shifts to povorcitinib's Phase 3 readout for hidradenitis suppurativa.

Incyte and Syndax Pharmaceuticals secure FDA approval for Niktimvo, a treatment for chronic graft-versus-host disease, with potential sales of $650 million.